Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care
Summary
- Buspirone and zolpidem should be started at a low dose in patients receiving cobicistat/elvitegravir/emtricitabine/tenofovir DF or cobicistat/elvitegravir/emtricitabine/tenofovir AF; dose reductions may be necessary[DHHS ART]
- Patients receiving cobicistat or ritonavir-boosted PIs in combination with zolpidem should also initiate zolpidem at a low dose[DHHS ART]
- Coadministration of suvorexant with PIs, cobicistat/elvitegravir/emtricitabine/tenofovir DF, or cobicistat/elvitegravir/emtricitabine/tenofovir AF is not recommended[DHHS ART]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Drug-Drug Interactions, Pharmacokinetics